Pair Name	Homoharringtonine, Suberoylanilide hydroxamic acid (SAHA)
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BID	hsa637
	Up-regulation	Activity	CASP3	hsa836
	Up-regulation	Activity	CASP8	hsa841
	Up-regulation	Activity	CASP9	hsa842
	Up-regulation	Expression	CYCS	hsa54205
	Up-regulation	Acetylation	H3C14	hsa126961
	Up-regulation	Acetylation	HRH4	hsa59340
	Up-regulation	Activity	PARP1	hsa142
	Up-regulation	Expression	TNFRSF10B	hsa8795
	Up-regulation	Expression	TNFSF10	hsa8743
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	Kasumi-1	Childhood acute myeloid leukemia with maturation	Homo sapiens (Human)	CVCL_0589
	THP-1	Childhood acute monocytic leukemia	Homo sapiens (Human)	CVCL_0006
In Vivo Model	3 to 4-week-old female mice were inoculated subcutaneously with 1×10⁷ THP-1 cells (in 0.1 ml volume) into the hind flanks.
Result	The synergistic effect between HHT and SAHA was blocked partially using a specific anti‑TRAIL antibody. The combination therapy was also found to significantly inhibit the growth of leukemia xenografts in vivo with enhanced apoptosis. These results indicate that, by regulating the induction of TRAIL and activation of the TRAIL apoptotic pathway, it is possible to administer HHT at low concentrations in combination with SAHA as an effective therapeutic approach for the treatment of AML.